<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706493</url>
  </required_header>
  <id_info>
    <org_study_id>PER 3312007</org_study_id>
    <nct_id>NCT05706493</nct_id>
  </id_info>
  <brief_title>Association Between Periodontitis and the Level of Anti-citrullinated Protein Antibodies in Rheumatoid Arthritis</brief_title>
  <official_title>Association Between Severity of Periodontitis and the Level of Anti-citrullinated Protein Antibodies (ACPAs) in Rheumatoid Arthritis Patients Before and After Non-surgical Periodontal Treatment (Pre and Post Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Misr International University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the relationship between rheumatoid arthritis and periodontal disease is crucial and has been&#xD;
      explained via a complex interplay of genetic, environmental, and hormonal factors that&#xD;
      influence the host immune tolerance leading to both disease characteristics. The aim of this&#xD;
      study is to clinically investigate the correlation between the levels of anti-citrullinated&#xD;
      protein antibodies (ACPAs) in gingival crevicular fluid before and after non-surgical&#xD;
      periodontal treatment and the severity of periodontal disease and rheumatoid arthritis in&#xD;
      rheumatoid arthritis (RA) patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the relationship between rheumatoid arthritis and periodontal disease is crucial and has been&#xD;
      explained via a complex interplay of genetic, environmental, and hormonal factors that&#xD;
      influence the host immune tolerance leading to both disease characteristics.&#xD;
&#xD;
      The aim of this study is to clinically investigate the correlation between the levels of&#xD;
      anti-citrullinated protein antibodies (ACPAs) in gingival crevicular fluid before and after&#xD;
      non-surgical periodontal treatment and the severity of periodontal disease and rheumatoid&#xD;
      arthritis in rheumatoid arthritis (RA) patients Materials and Methods: a total of 40&#xD;
      participants suffering from periodontitis and rheumatoid arthritis will be referred from the&#xD;
      Badr Hospital (Faculty of Medicine, Helwan University) to Misr international university's&#xD;
      dental clinic complex. Gingival crevicular fluid (GCF) samples will be collected from the&#xD;
      patients before performing periodontal therapy (baseline). Assessment of ACPAs will be&#xD;
      quantified using enzyme-linked immunoassay (ELISA) as the primary outcome at baseline and&#xD;
      after 3 months. Assessment of 2ry outcomes includes clinical periodontal and RA parameters at&#xD;
      baseline and after 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2023</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>According to the periodontal parameters measured the cases will be categorized according to the latest classification of the 2017 World Workshop of classification of periodontal diseases and conditions as follows: staging of periodontitis is mainly based on the interdental CAL at the site of greatest loss and on radiographic bone loss and on tooth loss, over 4 stages-stage I, initial; stage II, moderate; stage III, severe; and stage IV, advanced periodontitis, Patient periodontal status will be assessed using William's graduated periodontal probe.Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>there will be two outcome assessor one before the non surgical periodontal treatment and the other one will be after non surgical periodontal treatment with 3 months</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the level of anti-citrullinated protein antibodies (ACPAs)</measure>
    <time_frame>at baseline and 3 months</time_frame>
    <description>assessment of the level of anti-citrullinated protein antibodies (ACPAs) in gingival crevicular fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical attachment Loss</measure>
    <time_frame>at baseline and 3 months</time_frame>
    <description>measuring the distance from the cemento enamel junction to the base of the pocket in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Probing depth</measure>
    <time_frame>at baseline and 3 months</time_frame>
    <description>measuring the distance from the gingival margin to the base of the pocket in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plaque index (PI)</measure>
    <time_frame>at baseline and 3 months</time_frame>
    <description>it is a score (0,1,2 and 3) where: 0 = No plaque in the gingival area. 1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface. 2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. 3 = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Periodontal Diseases</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Non-surgical periodontal treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>assessment of different periodontal parameters and gingival crevicular fluid sampling will be done then non surgical periodontal treatment will be performed then after 3 months re assessment of the periodontal parameters and gingival crevicular fluid sampling will be done</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non surgical periodontal treatment</intervention_name>
    <description>Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes</description>
    <arm_group_label>Non-surgical periodontal treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid patients fulfilling the ACR criteria for the classification of RA&#xD;
&#xD;
               -  18 years&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Presence of at least 8 teeth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Patients who had undergone periodontal treatment within last 3 months&#xD;
&#xD;
          -  Antibiotic therapy during last 3 months&#xD;
&#xD;
          -  Other autoimmune diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zainab Hafez, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer, faculty of oral and dental medicine misr international university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yahia Hassan, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer, faculty of oral and dental medicine misr international university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahinaz Al ashiry, asso.Prof</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor, faculty of oral and dental medicine misr international universit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zainab Hafez, Lecturer</last_name>
    <phone>+01221334637</phone>
    <email>zeinab.hafez@miuegypt.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yahia Hasssan, Lecturer</last_name>
    <email>yahia.hassan@miuegypt.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of oral and dental medicine, Misr international university</name>
      <address>
        <city>Cairo</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zainab Hafez, Lecturer</last_name>
      <phone>+201221334637</phone>
      <email>zeinab.hafez@miuegypt.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Yahia amer, Lecturer</last_name>
      <email>yahia.hassan@miuegypt.edu.eg</email>
    </contact_backup>
    <investigator>
      <last_name>Zainab Hafez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yahia Hassan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 23, 2023</study_first_submitted>
  <study_first_submitted_qc>January 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>March 14, 2023</last_update_submitted>
  <last_update_submitted_qc>March 14, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>periodontitis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>anti citrullinated protein antibodies</keyword>
  <keyword>peptidyl arginine deminase enzyme</keyword>
  <keyword>gingival crevicular fluid (GCF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

